8-K: LAMY Acquires Exousia Ai, Pivots to Exosome Biotech

LAMY completed the acquisition of Exousia Ai, Inc., shifting its business focus to clinical-stage biotechnology developing plant-based exosome therapies for oncology, dermatology, and anti-aging.

Summary

• LAMY acquired 100% of Exousia Ai, Inc., making it a wholly-owned subsidiary, in exchange for 62,223,000 shares of LAMY common stock.
• The acquisition resulted in a change of control, with Exousia Pro Holding Management, LLC becoming the majority shareholder (58.89%) of LAMY.
• LAMY's business plan now centers on Exousia Ai's exosome technology, with divisions for Biotech (oncology, specifically Glioblastoma multiforme GBM), Cosmeceutical (skincare), and Nutraceutical (anti-aging supplements).
• Exousia Ai received Orphan Drug Designation (ODD) from the U.S. FDA in November 2025 for its exosome-based GBM treatment.
• Matthew Dwyer was appointed as the new Sole Officer and Director, replacing Zhang Shengwu, effective November 17, 2025.
• Exousia Ai holds a license agreement with Progenicyte Japan CO., LTD. for a nucleic acid drug delivery system technology, incurring a monthly license fee of $16,667.
• The company has a limited operating history, a history of net losses, and negative operating cash flow, requiring additional financing to sustain operations.

Sentiment

Score: 6

Explanation: The acquisition of Exousia Ai and its promising exosome technology, particularly the FDA Orphan Drug Designation for GBM, represents a significant strategic pivot with high potential. However, this is heavily offset by the company's limited operating history, history of net losses, negative operating cash flow, and substantial need for future financing, coupled with intense competition and inherent risks of an early-stage biotech venture. The 'penny stock' status and lack of independent market studies also contribute to a cautious outlook.

Positives

• Acquisition of Exousia Ai, Inc. provides a new, potentially high-growth business in clinical-stage biotechnology.
• Exousia Ai received Orphan Drug Designation from the FDA for malignant Glioma (GBM) in November 2025, which can accelerate development and provide market exclusivity benefits.
• Proprietary plant-based exosome manufacturing and loading technology offers potential for diverse applications in medicine, agriculture, and food science.
• Established three distinct divisions (Biotech, Cosmeceutical, Nutraceutical) to target multiple high-value markets.
• The intellectual property portfolio includes a licensed nucleic acid drug delivery system and proprietary serotonin assays and exosome development protocols.
• Current cash reserves are anticipated to last in excess of twelve months under present operating expectations.

Negatives

• LAMY has a limited operating history and a history of net losses.
• The company currently has a negative operating cash flow and may continue to for the foreseeable future.
• Significant additional financing is required to fund operational needs and growth strategies, with no assurance of availability on favorable terms.
• Potential for substantial shareholder dilution from future equity financing.
• The company faces intense competition from larger, more established, and better-capitalized companies in the medical products development and consumer medical products industries.
• There is doubt about the company's ability to continue as a viable business due to lack of profitability.
• The company's exosome-based strategies are not based on independent market studies, relying instead on management's experience, judgment, and assumptions.
• The common stock is considered "Penny Stock," which may impair trading liquidity and is subject to high volatility.

Risks

• Limited operating history, history of net losses, and uncertainty of achieving or maintaining profitability.
• Negative operating cash flow and the need for additional financing, which may not be available or may result in shareholder dilution.
• Difficulties in obtaining financing from U.S. banks due to the nature of the business, specifically referencing the psilocybin industry.
• Doubt about the company's ability to continue as a viable business (going concern risk).
• Inability to obtain sufficient capital to implement the full business plan.
• Lack of a successful operating history makes future operating results difficult to forecast and investment speculative.
• Dependence on the continued service of the sole executive officer, Matthew Dwyer, with no employment agreement or key-man insurance.
• Inability to recruit and retain key personnel.
• Exosome-based strategies are not based on independent market studies, relying on management's assumptions which may prove incorrect.
• The Board of Directors may change company policies without shareholder approval.
• Competition from larger, more established, and better-capitalized companies.
• Planned consumer medical products will compete in highly competitive markets, leading to pressure on profit margins and market share.
• Risk of competitors developing significant research advantages or superior products.
• Adverse publicity or consumer perception of planned products could harm reputation and sales.
• Inability to develop and market products in a timely manner, or competitors achieving commercialization first.
• Planned products may not provide intended beneficial effects or could have harmful side effects.
• Marketing strategies for new products may not be successful.
• Potential for litigation and government investigations.
• Lack of third-party oversight over contracted manufacturing could lead to quality decline.
• Product liability and related risks, including potential for significant insurance and loss expenses.
• Risk of product recalls due to defects, side effects, or labeling issues.
• Inability to obtain and maintain protection of intellectual property rights, which are costly and subject to challenge.
• Future sales of common stock, or the perception of such sales, could reduce the market price.
• No economic benefit may be realized from common stock ownership.
• No intention to pay dividends in the foreseeable future.
• Common stock is "Penny Stock," which may impair trading liquidity and make it difficult for investors to sell shares.
• Common stock is thinly traded and its market price may become highly volatile due to various factors, including those unrelated to operations.
• As an issuer of penny stock, the company does not have the federal securities law safe harbor for forward-looking statements.

Future Outlook

The company believes the future of plant-based exosomes is rich with potential, envisioning them as a cornerstone of green biotechnology across medicine, agriculture, and food science. They expect significant advances in drug delivery, immunotherapy, vaccine development, nutraceuticals, gene therapy, cancer diagnosis and treatment, cosmetic applications, and environmental/agricultural benefits. The company aims for cost-effective and scalable production of plant-based exosomes.

Management Comments

• "The Companys Board of Directors had determined, after investigating the Exousia Ai opportunity, that the best interests of the Company and its shareholders would be best served by acquiring Exousia Ai."
• "We believe the future of plant-based exosomes is rich with potential. As technology advances, plant exosomes could become a cornerstone of green biotechnology, offering sustainable, efficient and biocompatible solutions across medicine, agriculture and food science, for example."
• "Our company views plant-based exosomes as having many potentially significant capabilities."
• "By combining the Licensed Technologies with the Proprietary IP, we believe we will be able to produce products that will be extremely effective in assisting in the treatment of many diseases, including certain cancers."
• "GBM is the most common and highly malignant central nervous system (CNS) tumor that currently lacks adequate treatment, according to the Companys management."
• "The Company believes that Mr. Dwyer is capable of serving in his positions with the Company, without any impairment."

Industry Context

The acquisition positions LAMY in the rapidly evolving and highly competitive biotechnology and consumer medical products industries, specifically focusing on exosome-based therapies. The market for exosomes, particularly plant-based, is an emerging field with significant potential across diverse applications like oncology, dermatology, and nutraceuticals. The FDA's Orphan Drug Designation for GBM treatment is a critical step, placing Exousia Ai among companies pursuing innovative solutions for rare diseases with unmet medical needs. However, the industry is dominated by larger, better-capitalized players, posing substantial competitive challenges for an early-stage company like LAMY.

Comparison to Industry Standards

• The company operates in a highly competitive industry with larger, more established, and better-capitalized competitors.
• Many potential competitors possess greater financial, technical, personnel, promotional, and marketing resources, longer operating histories, greater name recognition, and larger consumer bases.
• The company expects significant competitive pricing pressures and products from other companies.
• No specific comparable companies, projects, or results are mentioned in the filing for direct comparison.

Management Changes

Corporate Governance

Legal Proceedings

• Acquired Corporation is not party to, nor has it been threatened with, any litigation or governmental proceeding.
• Acquired Corporation is not infringing on, or otherwise acting adversely to, any copyrights, trademark rights, patent rights or licenses owned by any other person, and there is no pending claim or threatened action with respect to such rights.
• The company acknowledges that it may, from time to time, receive inquiries and subpoenas and other types of information requests from government authorities and others and may become subject to claims and other actions related to its business activities.

Related Party Transactions

• The Company shares its principal office and lab space with Exousia Pro, Inc., its majority shareholder, at monthly rentals of $150 and $2,160.83, respectively.
• Exousia Pro Holding Management, LLC, a wholly-owned subsidiary of Exousia Pro, Inc., became the majority shareholder of LAMY (58.89%) through the acquisition.
• Matthew Dwyer, the new Sole Officer and Director of LAMY, has served as President of Exousia Pro, Inc. since April 2025.

Stakeholder Impact

• Shareholders: Significant dilution from the acquisition shares (62,223,000 shares issued). Potential for further dilution from future capital raises. Change of control shifts influence to new majority shareholder. Investment is speculative due to limited operating history and financial risks. No dividends expected. Penny stock status and thin trading may affect liquidity and price volatility.
• Employees: Current employees consist of one executive and one lab technician. Expectation to hire a small number of additional employees if funding is obtained. Dependence on the sole executive officer is a risk.
• Customers: Potential for new exosome-based products in biotech, cosmeceutical, and nutraceutical markets. Risks related to product efficacy, side effects, and recalls.
• Suppliers: Intends to source mammalian exosomes from US suppliers, expecting no difficulties.
• Creditors: Company has a history of net losses and negative operating cash flow, requiring additional financing, which could impact creditworthiness.

Next Steps

• File financial statements of Exousia Ai not later than 71 days after the closing of the Reorganization Agreement.
• File pro forma financial information not later than 71 days after the closing of the Reorganization Agreement.
• Transition from an early-stage company to one capable of supporting larger-scale commercial activities.
• Increase product sales.
• Obtain needed capital.
• Hire a small number of additional employees if additional funding is obtained.
• Continue using services of outside consultants and advisors.
• Advance cancer therapy into next clinical phases following Orphan Drug Designation.
• Optimize plant exosomes as delivery systems for chemotherapeutic agents, RNA-based therapies, and immune modulators.
• Develop plant exosome-based vaccines and immune therapies.
• Develop new, plant-derived functional foods or supplements.
• Engineer plant exosomes to deliver RNA therapies for genetic disorders.
• Develop plant exosome-based diagnostics and targeted cancer therapies.
• Create new anti-aging formulations, wound healing products, and skin regeneration therapies using plant exosomes.
• Utilize plant exosomes in agriculture for pest control, enhanced crop resistance, and improved plant growth.

Key Dates

Recommendation

The acquisition of Exousia Ai and its promising exosome technology, particularly the FDA Orphan Drug Designation for GBM, represents a significant strategic pivot with high potential for future growth. This positive development is, however, balanced by the company's early-stage nature, limited operating history, history of net losses, negative operating cash flow, and substantial need for future financing, which carries dilution risk. The highly competitive industry and the 'penny stock' status also present considerable challenges and volatility. Given the high-risk, high-reward nature of early-stage biotechnology coupled with significant financial uncertainties, a 'hold' recommendation is appropriate for investors who are already exposed or considering a speculative position, allowing time to observe the execution of the new business plan and progress on clinical development and financing, while acknowledging the substantial risks involved.

Keywords

Exosome, Biotechnology, Oncology, Glioblastoma Multiforme, GBM, Orphan Drug Designation, FDA, Cosmeceutical, Skincare, Nutraceutical, Anti-aging, Plant-based exosomes, Drug delivery, Gene therapy, Immunotherapy, Intellectual property, Acquisition, Corporate governance, Matthew Dwyer, LAMY, Exousia Ai